Genmab — Juli 2025

[E_L]

the Tepezza EMA EPAR - Public assessment report for those interested -153 pages- https://www.ema.europa.eu/en/documents/assessment-report/tepezza-epar-public-assessment-report_en.pdf

[E_L]

Roche YTD June 2025 https://assets.roche.com/f/176343/x/3e163d97e6/250724_ir_hy.pdf CHF mn Ocrevus 3,506 8% , Columvi 123 88% , Lunsumio 48 33%

[lahn1]

No doubt, AI like chat gpt is making mankind dummer, but I do love getting a one page summery of a 153 page report. LOL

[ProinvestorNEWS]

I dag, torsdag den 24. juli 2025, er en helt speciel dag for mange aktieinvestorer. For C25 er efter en hård 2025 endelig i plus igen. Helge Larsen ser på årsagerne og omtaler Novo Nordisk, Zealand Pharma, ISS, Vestas, Carlsberg og Bavarian Nordic. Og så slutter han af med flere gode nyheder, her fra Anavex, som i går steg 20 procent. Kort video: https://proinvestor.com/boards/127342/

[E_L]

Small new trial - A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) https://clinicaltrials.gov/study/NCT07082868

[w]

Uden jinxe for meget, så har vi vel brudt den lange nedtrend for første gang i 2.5år

[ProinvestorNEWS]

Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma https://proinvestor.com/investornyt/1342936/sanofis-sarclisa-combination-gets-eu-approval-for-treating-newly-diagnosed-multiple-myeloma

[BSinvest]

w... Aktien stadig er i en nedadgående trend. Afvent et brud over 1.650 DKK for at bekræfte en potentiel vending.

[BSinvest]

Vendingen skal helst ske med stigende RSI og øget handelsvolumen for at bekræfte at trenden for alvor er stigende.

[E_L]

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade https://www.nature.com/articles/s41598-025-11990-z

[gentogen]

The study of this was terminated prior to the start of the Dose Expansion Phase.NCT05435339. Many positive things in the article, but I kind of lack a coclusion about the development as ended or not?

[E_L]

They discontinued the clinical development.

[E_L]

this is what it said last august24: Following a strategic evaluation of GEN1053 within the context of
Genmab’s and BioNTech’s portfolios, a decision was made to discontinue the Phase 1/2 clinical trial
(NCT05435339) of GEN1053 in solid tumors. Preclinical activities remain ongoing.

[E_L]

whether those preclinical activities aim to return with something on Hexabody-CD27 I don't know (but i doubt it). Maybe it is to get more info on the Hexabody technology

[E_L]

But both Özlem Türeci & Uğur Şahin from biontech co-authored it, so they must have deemed it of interest

[gentogen]

Thanks a lot for the extra info.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[ProinvestorNEWS]

Genmab Transcript Special Call: Ser Rina-S i markedet i 2027 med peak-salg på 2 mia. USD https://proinvestor.com/investornyt/1343403/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-pa-2-mia-usd

[Bulder]

Tak til ØU for fremskaffelse og udarbejdelse af fortrinligt materiale.